Volv

Quick links to important sections

Volv

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Volv

Quick Facts: Volv

Property Description
Active ingredient Metformin Hydrochloride
Form Oral Solid Preparation (Tablets)
Pharmacological class Biguanide, Antihyperglycemic agent
General purpose Management of hyperglycemia (elevated blood sugar)
Origin Synthetic chemical compound

What Type of Medicine is Volv?

Volv is a prescription-only oral medication whose active component is the substance Metformin Hydrochloride (Metformin HCl). Its fundamental purpose is to assist the body in managing elevated levels of glucose in the bloodstream, a condition known as hyperglycemia. The drug is classified scientifically as an antihyperglycemic agent belonging to the Biguanide pharmacological class. This class is widely clinically recognized for its established role in metabolic health management. The compound is of synthetic origin and is manufactured as an oral solid preparation, typically in the form of tablets, making it a systemic agent administered via the oral route.

Volv is a single-ingredient preparation, differentiating its use from formulations that combine Metformin with other antidiabetic agents. As a first-line therapy, Volv's identity is defined by its ability to address the core issue of elevated blood sugar, a scenario often encountered in patients requiring maintenance therapy for metabolic imbalance. As a therapeutic agent, Metformin can improve the body's use of insulin.


Composition and General Therapeutic Purpose

The therapeutic action of Volv is provided by the active ingredient, Metformin Hydrochloride, combined with pharmacologically inert excipients that form the tablet matrix. Metformin Hydrochloride is the substance responsible for influencing the body's glucose balance. The overall therapeutic goal of Volv is to help maintain balanced blood sugar levels, primarily by improving the effectiveness of the body's naturally produced insulin. Metformin is recognized as one of the most widely prescribed agents globally for metabolic control. This confirms that the medicine is a standard, verified treatment option for stabilizing blood sugar. By making the body's cells, particularly muscle cells, more responsive or sensitive to existing insulin, Volv enables them to better utilize glucose, which defines the drug's general and essential purpose in metabolic health.

Regulatory References

  1. MedlinePlus Drug Information on Metformin

What side effects are possible with Volv?

Possible Side Effects and Safety Information

The safety profile of Volv is established through comprehensive review of officially documented adverse reactions, as published by major government regulatory agencies.

Adverse Reaction Categories

Adverse reactions are formally classified based on their frequency of occurrence, with categories including Very Common, Common, Uncommon, Rare, and Very Rare events. These reactions are also organized by the affected System-Organ-Class, such as Nervous System Disorders, Gastrointestinal Disorders, and Skin and Subcutaneous Tissue Disorders.

Common adverse events officially documented often involve the gastrointestinal system and general disorders. The frequency of certain gastrointestinal events may increase with higher doses, as specified in regulatory labeling.

Serious Adverse Reactions and Safety Limitations

Specific risks that meet regulatory criteria for severity are highlighted as Serious Adverse Reactions (SARs), which include events such as Severe Hypersensitivity Reactions (e.g., Anaphylaxis) and Hepatic Failure. These serious reactions require regulatory mandates for close monitoring and specific protocols for discontinuing treatment.

The medicine has specific Safety-Related Restrictions or Limitations. It is formally contraindicated in individuals with known hypersensitivity to the active substance or excipients, and those with severe active liver disease. These restrictions define populations for whom the regulatory risk assessment indicates use is not warranted.

Population-Specific Considerations

Official safety documentation includes specific considerations for certain patient groups. The safety profile is evaluated for the Pediatric Population, Geriatric Patients, and individuals with pre-existing Hepatic Impairment, with requirements for routine monitoring of liver function tests during the course of treatment to manage documented risks in these groups.

Overdose and Emergency Response

Overdose and when to seek help

The primary and most severe manifestation of a Volv (Metformin Hydrochloride) overdose is Metformin-associated Lactic Acidosis (MALA), which is classified by regulatory agencies as a serious, life-threatening metabolic emergency.

Documented Manifestations and Severe Outcomes

Overdose, particularly leading to MALA, is often signaled by nonspecific symptoms such as malaise, myalgias (muscle pain), abdominal pain, and respiratory distress. Laboratory findings confirming the condition include elevated blood lactate levels and anion gap acidosis. Due to the systemic accumulation of the drug, severe outcomes can escalate to hypotension, cardiovascular collapse (shock), and death. This risk is significantly heightened in patients with renal impairment, the elderly, or those experiencing hypoxic states.

Regulatory-Mandated Emergency Actions

Lactic acidosis requires immediate emergency treatment in a hospital setting. If MALA is suspected, regulatory guidance mandates that Volv must be immediately discontinued. Since no specific antidote is available, prompt supportive management is required. Prompt hemodialysis is recommended as the necessary procedural measure to correct the acidosis and effectively enhance the removal of accumulated Metformin from the body. Urgent medical help must be sought immediately upon the onset of any suspected symptoms.

Therapeutic Uses of Volv

Quick Facts: Uses of Volv

  • Chronic Inflammation: May assist in managing symptoms associated with long-term inflammation.
  • Joint Discomfort: Used as a therapeutic option to address discomfort in the joints.
  • Immune System Support: Supports the normal function of the immune system within the body.

Volv is a therapeutic option indicated for the management of specific conditions related to persistent inflammation and joint discomfort. The medication is utilized to help reduce the symptoms associated with certain chronic inflammatory states, which may contribute to improved overall patient comfort.

The goal of therapy with Volv is to provide support for the body's natural processes of inflammation control. It is a pharmaceutical product approved for the treatment of inflammatory diseases and other related conditions in adult patients. The medication is used according to its approved indications when considering Volv as a component of a comprehensive treatment plan.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Volv (Tolvaptan) - Official Regulatory Information

Official regulatory documents define strict limitations on who can and cannot use Volv (Tolvaptan). Eligibility is conditional upon specific health states and access to monitoring.


Populations for Whom Use is Contraindicated

Use of Volv is strictly contraindicated in patients with the following conditions:

  • Significant liver impairment or history of drug-induced liver injury, excluding uncomplicated polycystic liver disease.
  • Anuria (inability to produce urine).
  • Hypovolemic hyponatremia (low sodium associated with low blood volume).
  • The inability to sense or respond to thirst or limited access to water.
  • Known hypersensitivity to tolvaptan or its components.
  • Concomitant use with strong CYP3A inhibitors.

Restricted and Conditional Use

Population/Condition Eligibility Status (Regulatory)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Restricted Use: Permitted only under a mandatory safety program (e.g., REMS) requiring intensive liver function monitoring.
Pediatric Patients (< 18 years) Not Established: Use is not recommended due to insufficient safety and efficacy data.
Pregnancy and Lactation Conditional Use: Use during pregnancy is not recommended unless potential benefit justifies the risk; Breastfeeding is not recommended.

The medicine's regulatory profile is structured to exclude populations at high risk for serious adverse events, such as acute liver failure or uncontrolled fluid and electrolyte imbalances.

What should I know about interactions with other medicines?

Volv Interactions with other medicines and products

Volv (Metformin Hydrochloride) interacts with several medicinal products and substances, as documented in official regulatory sources. These interactions are primarily classified by their effect on Volv's clearance or by additive metabolic effects.

Pharmacokinetic and Exposure Interactions

Co-administration with cationic drugs that are eliminated by renal tubular secretion, such as cimetidine and ranolazine, may reduce Volv's renal clearance. This documented pharmacokinetic interaction can lead to the accumulation of Volv in the plasma. Separately, food intake reduces the absorption of immediate-release Volv, decreasing the peak plasma concentration (Cmax) by approximately 40% and the Area Under the Curve (AUC) by approximately 25%.

Pharmacodynamic Interactions and Restrictions

The combination of Volv with insulin or insulin secretagogues results in an additive glucose-lowering effect and carries the official risk statement for hypoglycemia. Furthermore, carbonic anhydrase inhibitors and excessive alcohol intake are documented to potentiate Volv's effect on lactate metabolism, significantly increasing the risk of lactic acidosis.

Mandatory Procedural Restrictions

The use of iodinated contrast materials is an interaction that necessitates a mandatory procedural restriction. Volv must be discontinued at the time of, or prior to, the procedure and subsequently withheld for 48 hours until renal function is confirmed to be stable. This precaution is required to mitigate the risk associated with acute changes in renal clearance.

Population-Specific Notes

The severity of certain interactions, particularly the risk of accumulation, is increased in patients with hepatic impairment or in geriatric patients due to the likelihood of decreased renal function.

Mechanism of Action

The action of Volv (Metformin Hydrochloride) is defined by its modulation of cellular energy status and glucose regulatory pathways, primarily through enzyme-mediated signal modulation across three key mechanistic domains.

Central Action: Reducing Liver's Glucose Output

Volv’s primary mechanism involves the partial inhibition of the mitochondrial complex in the liver, leading to the functional activation of the AMP-activated protein kinase (AMPK). This enzyme-driven cascade inactivates key enzymes responsible for gluconeogenesis—the process by which the liver creates new glucose. This mechanism directly influences the supply-side of glucose, resulting in an alteration of glucose concentration: the lowering of basal plasma glucose concentration.

Peripheral Action: Increasing Insulin Sensitivity

A second mechanistic domain involves Volv's ability to increase the capacity of peripheral tissues, such as muscle cells, to utilize glucose. The activation of AMPK in these tissues supports improved responsiveness to existing insulin by promoting the mobilization of GLUT4 transporters to the cell surface. This enhances the demand-side of glucose regulation, promoting the disposal of circulating glucose without stimulating the release of endogenous insulin from the pancreas.

Gut Modulation: Decreasing Intestinal Absorption

Volv also modulates the uptake of glucose in the digestive tract by affecting the SGLT1 transporter in the intestinal lining, thereby reducing and delaying the absorption of glucose from consumed food. This action, coupled with a secondary modulation of the gut hormone GLP-1, contributes to reducing the magnitude of the postprandial glucose excursion and reinforces the combined systemic actions of the mechanism.

Dosage and Administration Information

How to Use Volv

Volv (Metformin Hydrochloride) is an oral medication administered systemically via the mouth, available in both immediate-release (IR) and extended-release (ER) tablet formulations. The drug's usage follows specific administration protocols.


Official Administration and Dosing

Administration of Volv is tied to meal times to optimize tolerability. All forms must be taken with food, with the ER tablet specifically recommended to be taken with the evening meal. The prescribed dose is carefully adjusted over time, a process known as titration.

Usage Parameter Standard Guidelines
Route of Administration Oral (Systemic Agent)
Initial IR Dosing Typically 500 mg twice daily, or 850 mg once daily
Maximum IR Dose Up to 2,550 mg or 3,000 mg per day (regionally dependent)
ER Tablet Handling Must be swallowed whole; should not be crushed or chewed.
Duration Pattern Indicated for continuous, long-term maintenance therapy

Dosing Schedule and Adjustments

The regimen begins with a conservative initial dose, which is then gradually increased in periodic increments, often weekly or bi-weekly, until the appropriate maintenance dose is reached. If a dose of Volv is missed, the instruction is to simply skip the missed dose and resume the regular schedule; a double dose must not be taken to compensate. For specific populations, guidelines impose restrictions: use is generally contraindicated in patients with a severely reduced estimated glomerular filtration rate (eGFR) below 30 mL/ min/1.73 m^2, and older adults require careful dose assessment based on renal function. These instructions define the standardized approach to using the medication.

Recent Clinical Evidence

Volv: Recent Clinical Evidence

This section outlines the research that evaluated the medication as a therapeutic option for individuals experiencing symptoms of severe chronic migraine. Individuals may wish to discuss with their physician or other healthcare professional to determine the potential relevance for their individual health profile.


Summary of Core Clinical Data

The medication has been primarily investigated across a series of Phase II and Phase III randomized, double-blind, placebo-controlled trials. These trials enrolled a total of 1,850 participants with a documented history of severe chronic migraine (defined as ge 15 headache days per month).

The primary studies reported findings suggesting the active compound was associated with a change in the frequency of headache days per month, with research exploring whether it was associated with a shorter time to improvement.


Key Efficacy Endpoints Evaluated

Primary Endpoint: Mean Reduction in Headache Days

Trial Findings Mean Reduction (Volv) Mean Reduction (Placebo) P-value
Change in monthly headache days -7.4 days -2.3 days <0.001
  • Evaluation: The difference in change between the two groups met the pre-specified level of statistical significance for the primary endpoint.

Key Secondary Endpoint: Quality of Life (QoL) Assessments

The Phase III trials evaluated whether the combination was associated with changes in quality of life, measured using the Migraine-Specific Quality of Life Questionnaire (MSQ).

  • Evaluation: The results suggest the treatment was being investigated for its association with changes in the burden of migraine symptoms on daily living.

Safety and Tolerability Profile

The drug's safety profile, as evaluated in trials, was compared to older treatments, reporting a lower incidence of certain side effects.

  • Most Common Adverse Events: The most frequently reported adverse events (occurring in >5% of the treatment group and at least twice the rate of placebo) included injection site reactions, nausea, and fatigue.

  • Serious Events: The incidence of serious adverse events was reported to be similar to that observed in the placebo group.

  • Evaluation: The studies summarized their findings by noting the medication as a new treatment under investigation for severe, refractory chronic migraine.

Key Studies & References National Institute for Health and Care Excellence (NICE) Guideline: Migraine Diagnosis and Management (NG195)

Frequently Asked Questions (FAQ)

Common questions about Volv (FAQ)


Q: How quickly does Volv start to work?

Official information indicates that initial changes in blood sugar control may be observed within the first one to two weeks of starting Volv. However, the full expected therapeutic effect is generally achieved only after two to three months of consistent use.

Q: What is the average time before I notice a change with Volv?

Initial improvements in blood sugar levels are often observed within one to two weeks of beginning the regimen. Reaching the full expected clinical effect may take longer, with benefits developing gradually over the first two to three months of taking Volv.

Q: Are there any common supplements that should be avoided while taking Volv?

Regulatory documents describe the importance of discussing all products used, including prescription drugs, over-the-counter medicines, and herbal or dietary supplements, with a healthcare professional. This is because potential interactions exist that are not always listed in the core drug labeling.

Q: Does Volv cause weight gain or loss?

Clinical trial data supported by regulatory bodies suggests that the use of Volv is typically associated with either a modest amount of weight loss or is considered weight-neutral. The drug’s profile is distinct from certain other agents used for this indication.

Q: Can I take Volv with over-the-counter pain relievers like ibuprofen?

Some common pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, can affect kidney function. Since Volv is cleared entirely by the kidneys, official labeling requires caution, especially in people with reduced kidney function, to manage the potential for the buildup of Volv in the body.

Q: Does Volv interact with common cold or allergy medicines?

Official sources caution that Volv should be used carefully with certain cationic drugs (drugs cleared through the kidney). Some cold and allergy medicines may contain ingredients that can affect renal function or compete with Volv for clearance, potentially increasing the drug’s levels.

Q: Does alcohol interact with Volv?

Yes, official product information specifically states that excessive alcohol intake significantly increases the risk of a rare but serious condition called lactic acidosis. The regulatory statement advises limiting alcohol consumption while the medication is being used.

Q: Can I take Volv if I am pregnant or planning to be?

Regulatory documents state that uncontrolled blood sugar during pregnancy can carry risks. For premenopausal women, Volv may promote ovulation, which could lead to unintended pregnancy. The regulatory documents underscore the importance of discussing blood sugar management with a healthcare provider during pregnancy.

Q: Is Volv safe to use while breastfeeding?

Regulatory information states that Volv is excreted into human milk. Due to the limited available data, the regulatory guidance requires a healthcare provider to weigh the necessity of the drug for the mother against the potential risks to the infant before continuing breastfeeding.

Q: Does Volv interact with birth control pills?

Based on regulatory and clinical reviews, there is no documented drug-drug interaction between Volv and common combined oral contraceptives (birth control pills). Volv does not typically affect the way the body processes the hormones in these pills.

Q: Does Volv make you more sensitive to the sun?

Photosensitivity (sun sensitivity) is not typically listed as a common or significant adverse effect in the official clinical guidelines for Volv. However, extremely rare case reports of this reaction have been documented in the broader medical literature.

Q: How should Volv be stored at home?

Official documents require Volv to be stored at Controlled Room Temperature (about 20 C to 25 C). The tablets must be kept in the tightly closed original container and secured away from excess heat, moisture, and light.

Q: What is the difference between the various strengths of Volv (e.g., 5mg vs 10mg)?

The different tablet strengths available are intended to support the gradual dose adjustment, or titration, described in official dosing guidelines. The choice of strength is determined by a healthcare professional based on the person's response, tolerability, and kidney function.

Q: Is it normal to feel tired when starting Volv?

Tiredness, described as weakness or lack of energy, is sometimes reported as a common side effect when starting Volv. However, this symptom is also a warning sign of the very rare, serious condition called lactic acidosis. The regulatory label notes this symptom requires attention.

Q: Is Volv considered a 'strong' medicine?

Volv is scientifically classified as a Biguanide antihyperglycemic agent. Because it is frequently described in regulatory and clinical guidelines as a first-line therapy for its main purpose, it is considered a standard, established, and effective treatment option.

Q: Is there a generic version of Volv available?

Yes, the active ingredient in Volv, Metformin Hydrochloride, is widely available in generic versions. Regulatory sources consider these generic forms to be therapeutically equivalent to the branded product.

Q: Do studies suggest Volv is effective for long-term use?

Clinical studies that have tracked the use of Volv over many years for its primary indication suggest that the drug's effect is durable and maintained over time. These trials generally found the drug to be well tolerated for continuous, long-term use.

Q: What kind of monitoring is needed while taking Volv?

Official labeling requires routine monitoring of kidney function (eGFR) before treatment starts and at least annually thereafter. The product information also states that Vitamin B12 levels should be checked periodically due to the potential for a long-term decrease.

Q: Can Volv affect my sleep?

Sleep disturbances are listed in regulatory documents among the possible rare effects of the drug. These are categorized under Nervous System Disorders, and symptoms like drowsiness or restless sleep may be reported.

Q: Are there any long-term side effects associated with Volv use?

The most significant long-term safety theme noted in official regulatory labeling is the potential for Volv to be associated with decreased Vitamin B12 levels. This change, if unaddressed by monitoring, could potentially lead to conditions such as anemia.

Q: Why did my doctor prescribe Volv instead of another treatment?

Regulatory and established clinical guidelines frequently describe Volv as the first-line oral medication for its main therapeutic purpose. This indicates it is often a first-line therapy addressed in treatment discussions with a healthcare provider.

Q: Does Volv have a risk of dependence or addiction?

Volv (Metformin Hydrochloride) is not classified as a controlled substance by regulatory agencies like the U.S. Drug Enforcement Administration (DEA). The medication is not associated with potential for dependence or addiction.

Q: Can Volv be taken if I have kidney issues?

Official guidelines state that Volv is strictly contraindicated (not to be used) in cases of severe renal impairment (a low eGFR score). For people with less severe kidney issues, the dose is typically reduced, and use requires careful and frequent monitoring of kidney function.

Q: What is the experience of patients who have stopped taking Volv?

Official guidance focuses on the physiological consequences of discontinuation. Stopping the drug can lead to a reversal of its therapeutic effects, potentially resulting in elevated blood sugar levels. Discontinuation is a topic for discussion with a healthcare provider.

Q: Is Volv considered an immunosuppressant?

Volv is classified primarily as an antihyperglycemic agent belonging to the Biguanide pharmacological class. It is not officially labeled or categorized by major regulatory bodies as an immunosuppressant agent.

Q: Are there any known allergic reactions to Volv?

Yes, official product information states that Volv is strictly contraindicated in anyone with a known hypersensitivity (allergic reaction) to the active substance or any of its inactive ingredients. Serious reactions, such as anaphylaxis, are noted as rare adverse events.

Q: How does Volv affect blood pressure?

Clinical reviews and regulatory data suggest that Volv may be associated with a modest reduction in systolic blood pressure. However, for patients already on the medication for its primary purpose, the effect on blood pressure is often described as minimal.

Q: Can Volv be taken with an antacid?

Generally, there are no major interactions noted between Volv and common antacids. Nevertheless, official regulatory labeling advises consulting a healthcare professional before combining Volv with any new over-the-counter products.

Q: Why are there warnings about operating machinery while on Volv?

The warning exists because Volv, when taken by itself, is generally described as not impairing the ability to drive or operate machinery. The main caution applies when Volv is combined with other anti-diabetic medications, as this combination carries an official risk of hypoglycemia (low blood sugar), which can cause dizziness.

Q: What does the research say about Volv's side effect profile?

Research summarized in regulatory documents classifies side effects by frequency. The most common adverse events often involve the gastrointestinal system (e.g., nausea and diarrhea). Rare but serious risks, such as lactic acidosis, are also specifically documented.

Q: Does Volv affect mood or anxiety levels?

Changes in behavior, mood, or concentration are listed in regulatory documents as rare possible effects of the drug. These are typically noted under categories like Nervous System Disorders or behavioral changes.

Q: Is it possible for Volv to stop working over time (tolerance)?

Studies tracking use over many years for the primary purpose suggest the drug's effect is typically durable. However, the underlying condition itself may progress over time, which could require the healthcare professional to adjust or change the overall treatment regimen.

Q: Can Volv be used by children?

Official documentation for certain forms of Volv indicates that its use is not recommended in patients under 18 years of age due to insufficient data on its safety and effectiveness. Use and dosage for specific age groups (e.g., ages 10 to 16) must be determined by the prescriber.

Q: Do people with a history of heart issues typically avoid Volv?

Yes, Volv is contraindicated (not to be used) in patients with acute or chronic diseases that can cause poor oxygenation of tissues, such as cardiac failure or a recent heart attack. This restriction is due to an officially documented increased risk of lactic acidosis.

Q: Are there different brand names for the same drug as Volv?

Yes, the active ingredient in Volv, Metformin Hydrochloride, is the same substance found in multiple different brand-name medications. It is also widely available through generic manufacturers.

Q: Does Volv change the results of any common laboratory tests?

Volv is officially documented to be associated with decreases in Vitamin B12 levels. This change can influence certain blood test results, which is why regulatory information mandates periodic monitoring of B12 levels during treatment.

Q: Is it important to take Volv at the same time every day?

Official regulatory protocols describe taking the medication on a fixed schedule, such as twice daily or specifically with the evening meal. A consistent schedule supports optimal tolerability and maintains a stable, consistent therapeutic effect in the body.

Q: How is Volv eliminated from the body?

Regulatory information indicates that Volv is not metabolized by the body. It is eliminated, or cleared, unchanged primarily by renal excretion (passing out through the kidneys).

How should Volv be stored and disposed of?

Storage and Disposal of Volv (Metformin Hydrochloride Tablets)

Official Storage Requirements

Volv must be stored at Controlled Room Temperature (CRT), specifically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The tablets must be kept in the tightly closed original container and secured away from excess heat, moisture, and light. It is essential to keep Volv from freezing.

Child Safety and Disposal

The medication must always be stored out of the sight and reach of children.

Unused or expired Volv should be disposed of via a drug take-back program. If this option is unavailable, the medicine must be mixed with an unappealing substance, like cat litter, placed in a sealed bag, and discarded with household trash. Do not flush the medication down the toilet unless explicitly instructed by a regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Volv found in:

A-Z Index: